Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896753 | 1.00 | GRM5 (0.42) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5440803 | 0.90 | GRM5 (0.41) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4347449 | 0.89 | NPC1 (0.38) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4347443 | 0.89 | NPC1 (0.38) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5433709 | 0.88 | KCNH2 (0.42) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2899420 | 0.88 | SCD (0.42) | GRM5USP30 | |
| SCHEMBL2899411 | 0.88 | SCD (0.42) | GRM5USP30 | |
| SCHEMBL4060315 | 0.87 | SMN1; SMN2 (0.40) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2899180 | 0.87 | SMN1; SMN2 (0.41) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2890710 | 0.86 | SMN1; SMN2 (0.40) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | GRM5 1/4885SMN1; SMN2 1207/4885NPC1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.